The Biochemical Society has announced Phil Morgan as its new Chief Executive Officer, succeeding Kate Baillie, who retired last week after over 12 years of service.
Phil Morgan joins the Society with extensive leadership experience, having previously served as CEO of The Institute of Physics and Engineering in Medicine (IPEM). During his four-and-a-half-year tenure at IPEM, Morgan spearheaded a strategic transformation, achieved significant growth across multiple areas, and navigated challenges associated with open access publishing.
The Biochemical Society expressed enthusiasm about Morgan’s appointment, emphasizing the collaborative efforts ahead. Society staff, along with its Committees, Panels, and Boards, are eager to work with Morgan as he leads initiatives to advance the Society’s strategic objectives and continues to support the global molecular bioscience community.
Morgan’s leadership is expected to build on the legacy of his predecessor, with a focus on fostering growth, innovation, and collaboration within the field.
Click here to read the original press release.
